TNYA

#3727
Tenaya Therapeutics, Inc. - Common Stock
0.6 9 USD
-0.01%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
0.69
0.71
Jahresspanne
0.53
2.35
Tagesänderung
-1.43%
Monatliche Änderung
-6.76%
6 month change
+21.05%
Jahresänderung
-41.03%
Vorheriger Schlusskurs
0.7 0
Open
0.7 0
Tief
0.6 9
Hoch
0.7 1
Volumen
153
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
Tenaya Therapeutics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Tenaya Therapeutics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Tenaya Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Tenaya Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Tenaya Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Tenaya Therapeutics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Tenaya Therapeutics, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Tenaya Therapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Tenaya Therapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Tenaya Therapeutics, Inc. current report, Q1 FY2026
8-K

Tenaya Therapeutics, Inc. current report, Q1 FY2025

Full document

Business Context and Reporting Period

Tenaya Therapeutics, Inc. (TNYA) filed a Current Report on Form 8-K dated February 6, 2025. The filing discloses corporate governance changes, specifically the appointment of an Interim Principal Accounting Officer and the repricing of underwater stock options for the Chief Executive Officer.

Key Financial Metrics

This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel appointments and equity compensation adjustments.

Material Changes

  • Appointment of Interim Principal Accounting Officer: Effective February 6, 2025, Tomohiro Higa, Senior Vice President, Finance, was appointed as Interim Principal Accounting Officer. He has served as SVP, Finance since January 2025 and previously as VP, Finance since January 2020.
  • CEO Option Repricing: The Board approved a repricing of underwater stock options for CEO Faraz Ali. Approximately 915,875 shares with exercise prices ranging from $5.64 to $15.19 were repriced to $1.21 per share.

Guidance, Outlook, and Risks

The filing does not provide financial guidance or outlook. Management commentary indicates the option repricing was designed to retain and motivate the CEO without incurring significant additional equity dilution or cash expenditures. A specific risk/condition attached to the repricing is the "Retention Goal Achievement": if Mr. Ali exercises the options before July 24, 2025, or a Change in Control occurs, he must pay a premium exercise price equal to the original pre-repricing price.

Investor Verification Checklist

  • Verify the total number of shares underlying the repriced options (approx. 915,875) and the new exercise price ($1.21).
  • Confirm the "Retention Date" of July 24, 2025, which dictates the premium exercise price condition.
  • Review the standard director and officer indemnification agreement referenced in the filing.
  • Check for any subsequent filings regarding the permanent appointment of a Principal Accounting Officer.

Nachrichten